Selected research
Market Structure
Global Rifaximin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Rifaximin market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Rifaximin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Rifaximin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Rifaximin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Rifaximin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Rifaximin include Texas Pharmaceuticals, STERIS PHARMA, Soigner Pharma, Salix Pharmaceuticals and Cassopeia Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Rifaximin market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Rifaximin and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Rifaximin sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Rifaximin market size, projected growth trends, production technologies, key applications, and end-use industries.
Rifaximin Segment by Company
Texas Pharmaceuticals
STERIS PHARMA
Soigner Pharma
Salix Pharmaceuticals
Cassopeia Pharmaceuticals
Rifaximin Segment by Type
200 mg Tablets
550 mg Tablets
Rifaximin Segment by Application
Hospital
Drug store
Rifaximin Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rifaximin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Rifaximin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rifaximin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Rifaximin market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Rifaximin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Rifaximin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Rifaximin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- 200 mg Tablets
- 550 mg Tablets
Applications
- Hospital
- Drug store
Companies covered
- Texas Pharmaceuticals
- STERIS PHARMA
- Soigner Pharma
- Salix Pharmaceuticals
- Cassopeia Pharmaceuticals
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Rifaximin Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Rifaximin Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Rifaximin Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Rifaximin Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Rifaximin Market Dynamics
- 2.1 Rifaximin Industry Trends
- 2.2 Rifaximin Industry Drivers
- 2.3 Rifaximin Industry Opportunities and Challenges
- 2.4 Rifaximin Industry Restraints
3 Rifaximin Market by Manufacturers
- 3.1 Global Rifaximin Revenue by Manufacturers (2021-2026)
- 3.2 Global Rifaximin Sales by Manufacturers (2021-2026)
- 3.3 Global Rifaximin Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Rifaximin Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Rifaximin Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Rifaximin Manufacturers, Product Type & Application
- 3.7 Global Rifaximin Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Rifaximin Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Rifaximin Players Market Share by Revenue in 2025
- 3.8.3 2025 Rifaximin Tier 1, Tier 2, and Tier 3
4 Rifaximin Market by Type
- 4.1 Rifaximin Type Introduction
- 4.1.1 200 mg Tablets
- 4.1.2 550 mg Tablets
- 4.2 Global Rifaximin Sales by Type
- 4.2.1 Global Rifaximin Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Rifaximin Sales by Type (2021-2032)
- 4.2.3 Global Rifaximin Sales Market Share by Type (2021-2032)
- 4.3 Global Rifaximin Revenue by Type
- 4.3.1 Global Rifaximin Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Rifaximin Revenue by Type (2021-2032)
- 4.3.3 Global Rifaximin Revenue Market Share by Type (2021-2032)
5 Rifaximin Market by Application
- 5.1 Rifaximin Application Introduction
- 5.1.1 Hospital
- 5.1.2 Drug store
- 5.2 Global Rifaximin Sales by Application
- 5.2.1 Global Rifaximin Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Rifaximin Sales by Application (2021-2032)
- 5.2.3 Global Rifaximin Sales Market Share by Application (2021-2032)
- 5.3 Global Rifaximin Revenue by Application
- 5.3.1 Global Rifaximin Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Rifaximin Revenue by Application (2021-2032)
- 5.3.3 Global Rifaximin Revenue Market Share by Application (2021-2032)
6 Global Rifaximin Sales by Region
- 6.1 Global Rifaximin Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Rifaximin Sales by Region (2021-2032)
- 6.2.1 Global Rifaximin Sales by Region (2021-2026)
- 6.2.2 Global Rifaximin Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Rifaximin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Rifaximin Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Rifaximin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Rifaximin Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Rifaximin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Rifaximin Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Rifaximin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Rifaximin Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Rifaximin Revenue by Region
- 7.1 Global Rifaximin Revenue by Region
- 7.1.1 Global Rifaximin Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Rifaximin Revenue by Region (2021-2026)
- 7.1.3 Global Rifaximin Revenue by Region (2027-2032)
- 7.1.4 Global Rifaximin Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Rifaximin Revenue (2021-2032)
- 7.2.2 North America Rifaximin Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Rifaximin Revenue (2021-2032)
- 7.3.2 Europe Rifaximin Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Rifaximin Revenue (2021-2032)
- 7.4.2 Asia-Pacific Rifaximin Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Rifaximin Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Rifaximin Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Texas Pharmaceuticals
- 8.1.1 Texas Pharmaceuticals Company Information
- 8.1.2 Texas Pharmaceuticals Business Overview
- 8.1.3 Texas Pharmaceuticals Rifaximin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Texas Pharmaceuticals Rifaximin Product Portfolio
- 8.1.5 Texas Pharmaceuticals Recent Developments
- 8.2 STERIS PHARMA
- 8.2.1 STERIS PHARMA Company Information
- 8.2.2 STERIS PHARMA Business Overview
- 8.2.3 STERIS PHARMA Rifaximin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 STERIS PHARMA Rifaximin Product Portfolio
- 8.2.5 STERIS PHARMA Recent Developments
- 8.3 Soigner Pharma
- 8.3.1 Soigner Pharma Company Information
- 8.3.2 Soigner Pharma Business Overview
- 8.3.3 Soigner Pharma Rifaximin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Soigner Pharma Rifaximin Product Portfolio
- 8.3.5 Soigner Pharma Recent Developments
- 8.4 Salix Pharmaceuticals
- 8.4.1 Salix Pharmaceuticals Company Information
- 8.4.2 Salix Pharmaceuticals Business Overview
- 8.4.3 Salix Pharmaceuticals Rifaximin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Salix Pharmaceuticals Rifaximin Product Portfolio
- 8.4.5 Salix Pharmaceuticals Recent Developments
- 8.5 Cassopeia Pharmaceuticals
- 8.5.1 Cassopeia Pharmaceuticals Company Information
- 8.5.2 Cassopeia Pharmaceuticals Business Overview
- 8.5.3 Cassopeia Pharmaceuticals Rifaximin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Cassopeia Pharmaceuticals Rifaximin Product Portfolio
- 8.5.5 Cassopeia Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Rifaximin Value Chain Analysis
- 9.1.1 Rifaximin Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Rifaximin Production Mode & Process
- 9.2 Rifaximin Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Rifaximin Distributors
- 9.2.3 Rifaximin Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst